Eye-level characteristics of the study population
| Case | Laterality | Group | Previous chemotherapy, with Nb cycles | Previous other treatment | SRS, before IViC | Vitreous seeding phenotype | IViC Nb injections | Total melphalan, dose (μg) | Other treatment during and/or after IViC | Event-free interval, from last treatment, months | Globe (patient) survival from 1st injection, months | ||
| Before IViC | After IViC | Chemotherapy | Other | ||||||||||
| 1 | B* | D | IVC6/IAC3/POC3/CTT1 | PRT2/focal | No | Diffuse relapse | CR Type 0 | 9 | 180 | None | PRT2/lensectomy (IOL) | 16 | 31 |
| 2 | U | C | IAC1/POC3 | Focal | No | Localised persistent | CR Type II | 3 | 60 | None | Focal | 24 | 28 |
| 3 | U | D | IAC3 | None | No | Diffuse persistent | PR | 8 | 160 | POC2/CTT2/aIVC4 | Enucleation PD | 17 | 11 (28) |
| 4 | B* | D | IAC3 | Focal | No | Diffuse persistent | CR Type 0 | 3 | 60 | None | Focal/buckle (RD) | 17.5 | 26 |
| 5 | B | D | IAC2 | None | Yes | Diffuse persistent | CR Type 0 | 4 | 80 | None | SCR/focal | 14 | 24 |
| 6 | B* | C | IVC4/POC1 | Focal | No | Diffuse relapse | CR Type III | 8 | 160 | CTT2 | Focal | 18 | 29 |
| 7 | B* | C | IVC3 | PRT1/focal | No | Diffuse relapse | CR Type 0 | 8 | 160 | None | Focal | 22 | 24 |
| 8 | B* | C | IVC6 | Focal | No | Localised relapse | CR Type I | 4 | 80 | None | Focal | 24 | 27 |
| 9 | U | B | IVC3/CTT1 | Focal | No | Localised relapse | CR Type 0 | 12 | 280 | None | PRT1/focal | 14 | 19 |
| 10 | U | D | IAC1 | None | No | Diffuse persistent | CR Type I | 8 | 162 | None | Focal | 19 | 24 |
| 11 | B* | D | IVC6 | Focal | No | Localised relapse | CR Type 0 | 2 | 40 | None | Focal | 23 | 24 |
| 12 | U | D | IAC1 | None | No | Localised persistent | CR Type 0 | 3 | 64 | IAC2 | Buckle (RD) | 17 | 24 |
| 13 | B* | D | IVC5 | None | Yes | Localised relapse | PR | 2 | 40 | aIVC4 | Focal/SCR/enucleation PD | 6 | 15 (21) |
| 14 | B* | C | IVC9 | Focal | No | Localised relapse | CR Type 0 | 3 | 70 | None | PRT1/focal | 17.5 | 20 |
| 15 | B* | D | IVC3/IAC3 | Focal | Yes | Diffuse relapse | CR Type I | 3 | 60 | None | None | 16 | 17 |
| 16 | B | B | IAC6/POC1 | Focal | No | Localised relapse | CR Type 0 | 8 | 176 | None | PRT1/focal | 4.5 | 17 |
| 17 | B* | C | IVC4/CTT4 | PRT1/focal | No | Localised relapse | CR Type 0 | 2 | 40 | None | Focal | 14.5 | 15 |
| 18 | B | B | IVC6/IAC3 | None | No | Localised relapse | CR Type I | 8 | 214 | None | None | 11 | 13 |
| 19 | B | C | IVC6/IAC1 | Focal | No | Localised relapse | CR Type 0 | 3 | 90 | IAC2 | Focal/†/Enucleation PB | 5 | 9 (14) |
| 20 | B | C | IVC6/IAC3/POC2 | Focal | No | Localised relapse | CR Type 0 | 4 | 96 | None | PRT1/focal | 10 | 14 |
| 21 | B | C | IVC9/IAC5/POC1 | Focal | Yes | Diffuse relapse | CR Type 0 | 8 | 234 | None | Focal/† | 3.5 | 10 |
| 22 | B | D | IVC6/IAC3/POC1 | Focal | Yes | Localised relapse | CR Type 0 | 4 | 88 | POC5 | Focal | 3 | 10 |
| 23 | B | D | IVC6/IAC4 | Focal | Yes | Diffuse relapse | CR Type III | 5 | 114 | POC1 | Focal | 7 | 9 |
↵* Previous enucleation fellow eye.
†anti-vascular endothelial growth factor injection.
aIVC, adjuvent intravenous chemotherapy; CTT, chemothermotherapy; IAC, intra-arterial chemotherapy (melphalan only); IOL, intraocular lens; IVC, intravenous chemotherapy; IViC, intravitreal chemotherapy; PB, phthisis bulbi; PD, progressive disease; POC, periocular chemotherapy; PRT, plaque radiotherapy; RD, retinal detachment; SCR, stereotactic conformal radiotherapy; SRS, subretinal seeds.
Focal treatments: Thermotherapy and/or photocoagulation and/or cryoapplication; PR, partial response; CR, complete response: type 0, no visible seeds; type I,: calcified seeds; type II, amorphous seeds; type III, combined type I + type II.